Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure

PHASE3CompletedINTERVENTIONAL

Enrollment

1,797

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions

Hypertension

Interventions

DRUG

aliskiren

Trial Locations (2)

Novartis Pharmaceuticals, East Hanover

Investigative Centers